Grifols, S.A. (NASDAQ:GRFS)

CAPS Rating: 3 out of 5

Results 1 - 2 of 2

Recs

0
Member Avatar GiantMonster (< 20) Submitted: 4/29/2013 11:37:38 AM : Outperform Start Price: $29.96 GRFS Score: -12.00

strong player in a consolidated market with growing demand

Recs

0
Member Avatar jspirz (< 20) Submitted: 2/26/2013 2:12:45 PM : Outperform Start Price: $27.88 GRFS Score: -11.19

Still realizing their potential after acquiring Talecris. Now a major player in the human plasma protein based therapy's.

Results 1 - 2 of 2

Featured Broker Partners


Advertisement